Thioguanine |
6-TG; TG |
Clinical Trial: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
This study is currently recruiting patients.
Purpose
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with that of prednisone during induction therapy and methotrexate with or without leucovorin during maintenance therapy in treating patients who have newly diagnosed acute lymphoblastic leukemia.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| untreated childhood acute lymphoblastic leukemia B-cell childhood acute lymphoblastic leukemia untreated adult acute lymphoblastic leukemia B-cell adult acute lymphoblastic leukemia | Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin Drug: dexamethasone Drug: doxorubicin Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: pegaspargase Drug: prednisone Drug: thioguanine Drug: vincristine Procedure: chemotherapy Procedure: high-dose chemotherapy Procedure: radiation therapy | Phase III |
MedlinePlus related topics: Leukemia, Adult Acute; Leukemia, Adult Chronic; Leukemia, Childhood
Study Type: Interventional
Study Design: Treatment
Official Title: Phase III Randomized Study of Dexamethasone Versus Prednisone During Induction and High-Dose Methotrexate With Leucovorin Rescue Versus Escalating-Dose Methotrexate Without Leucovorin Rescue During Interim Maintenance I in Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
OBJECTIVES:
- Compare the outcome of patients with high-risk acute lymphoblastic leukemia treated with 2 different chemotherapy regimens.
- Compare the relative safety and efficacy of dexamethasone vs prednisone during induction therapy in patients treated with these regimens.
- Compare the relative safety and efficacy of high-dose methotrexate with leucovorin rescue vs escalating methotrexate without leucovorin rescue during interim maintenance I in patients treated with these regimens.
- Correlate minimal residual disease (MRD) at day 29 with event-free survival and overall survival of patients treated with these regimens.
- Correlate early marrow response status with day-29 MRD in patients treated with these regimens.
- Identify additional high-risk patients for treatment with the fully augmented Berlin-Frankfurt-Munster regimen by using day-29 MRD.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to early response (slow early response [SER] vs rapid early response [RER]). Patients are randomized to 1 of 4 treatment arms.
Induction
- Patients receive intrathecal (IT) cytarabine on day 1; vincristine IV and daunorubicin IV on days 1, 8, 15, and 22; oral or IV dexamethasone twice daily on days 1-14; IT methotrexate (MTX) on days 8 and 29*; and pegaspargase intramuscularly (IM) once on day 4, 5, or 6. NOTE: *Patients with CNS3 disease (WBC > 5/mL in cerebrospinal fluid and positive for blasts on cytospin) also receive IT MTX on days 15 and 22.
- Arm II: Patients receive induction therapy as in arm I.
- Arm III: Patients receive cytarabine, vincristine, daunorubicin, and pegaspargase as in arm I. Patients also receive oral or IV prednisone twice daily on days 1-28 and IT MTX on days 8 and 29.
- Arm IV: Patients receive induction therapy as in arm III. Patients in all arms are evaluated at day 29 of induction. Patients with M3 disease are removed from study. Patients with M1 disease and less than 1% minimal residual disease (MRD) proceed to consolidation therapy beginning on day 36. Patients with M2 disease OR with MI disease and at least 1% MRD receive extended induction therapy for 2 additional weeks.
Extended induction therapy
- Arms I and II: Patients receive oral or IV dexamethasone twice daily on days 1-14; vincristine IV on days 1 and 8; daunorubicin IV on day 1; and pegaspargase IM on day 4, 5, or 6 and are then reevaluated.
- Arms III and IV: Patients receive oral or IV prednisone twice daily on days 1-14, and vincristine, daunorubicin, and pegaspargase as in arms I and II and are then reevaluated. Patients on all arms who have M1 disease and less than 1% MRD after extended induction proceed to consolidation therapy and continue as SER patients. All other patients are removed from study.
Consolidation therapy
- Patients receive cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV or subcutaneously (SC) on days 2-5, 9-12, 30-33, and 37-40; oral mercaptopurine (MP) on days 1-14 and 29-42; vincristine IV on days 15, 22, 43, and 50; pegaspargase IM on days 15 and 43; and IT MTX* on days 1, 8, 15, and 22. NOTE: *Patients with CNS3 disease receive MTX on days 1 and 8 only.
Interim maintenance I
- Arm I (escalating-dose MTX): Patients receive vincristine IV and escalating-dose MTX IV on days 1, 11, 21, 31, and 41; pegaspargase IM on days 2 and 22; and IT MTX on days 1 and 21.
- Arm II (high-dose MTX): Patients receive vincristine IV and high-dose methotrexate IV over 24 hours on days 1, 15, 29, and 43; leucovorin calcium IV every 6 hours for at least 3 doses, beginning 42 hours after start of each MTX infusion; oral MP on days 1-56; and IT MTX on days 1 and 29.
- Arm III (escalating-dose MTX): Patients receive interim maintenance I therapy as in arm I.
- Arm IV (high-dose MTX): Patients receive interim maintenance I therapy as in arm II.
Delayed intensification I
- Arms I-IV: Patients receive vincristine IV on days 1, 8, 15, 43, and 50; oral or IV dexamethasone twice daily on days 1 to 21 for patients age 1 to 12 OR on days 1-7 and 15-21 for patients age 13 and over; doxorubicin IV on days 1, 8, and 15; pegaspargase IM on day 4, 5, or 6 AND day 43; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV or SC on days 30-33 and 37-40; oral thioguanine on days 29-42; and IT MTX on days 1, 29, and 36. After delayed intensification I, SER patients proceed to interim maintenance II and delayed intensification II. RER patients proceed directly to maintenance.
Interim maintenance II
- Arms I-IV: Patients receive vincristine IV and MTX IV on days 1, 11, 21, 31, and 41; pegaspargase IM on days 2 and 22; and IT MTX on days 1 and 21. Patients then proceed to delayed intensification II.
Delayed intensification II
- Arms I-IV: Patients receive therapy as in delayed intensification I, arm I. CNS3 patients also receive radiotherapy for 3-10 days, beginning on day 29. All other SER patients receive prophylactic cranial radiotherapy for 8 days, beginning on day 29. Patients then proceed to maintenance therapy.
Maintenance therapy
- Patients receive vincristine IV on days 1, 29, and 57; oral dexamethasone twice daily on days 1-5, 29-33, and 57-61; oral MP on days 1-84; IT MTX on day 1*; and oral MTX on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. NOTE: *RER patients also receive IT MTX on day 29 for maintenance courses 1-4.
Patients with testicular disease may receive testicular radiotherapy for 8 days during one of the first 3 courses of maintenance therapy.
In all arms, maintenance therapy repeats every 12 weeks until total duration of therapy is 2 years from the start of interim maintenance I for female patients and 3 years from the start of interim maintenance I for male patients.
Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 2,292 patients (573 per treatment arm) will be accrued for this study within 4 years.
Eligibility
Ages Eligible for Study: 1 Year - 30 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Newly diagnosed B-precursor acute lymphoblastic leukemia
- WBC > 50,000/mm^3 for patients age 1 to 9
- Any WBC for patients age 10 to 30 OR patients who have received prior steroid therapy
- Must be eligible for and enrolled on classification study COG-AALL03B1
PATIENT CHARACTERISTICS: Age
- 1 to 30
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY: Biologic therapy
- Not specified
Chemotherapy
- No more than 72 hours since prior intrathecal cytarabine
- No other prior cytotoxic chemotherapy
Endocrine therapy
- Prior steroids allowed
Radiotherapy
- Not specified
Surgery
- Not specified
Location and Contact Information
Alabama
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35233, United States; Recruiting
University of South Alabama Cancer Research Institute, Mobile, Alabama, 36604, United States; Recruiting
Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, 85724, United States; Recruiting
Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States; Recruiting
Arkansas
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States; Recruiting
California
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, 92868, United States; Recruiting
Children's Hospital and Health Center, San Diego, San Diego, California, 92123-4282, United States; Recruiting
Children's Hospital and Research Center at Oakland, Oakland, California, 94609-1809, United States; Recruiting
Children's Hospital Central California, Madera, California, 93638-8762, United States; Recruiting
Children's Hospital Los Angeles, Los Angeles, California, 90027-0700, United States; Recruiting
Children's Hospital of Orange County, Orange, California, 92868, United States; Recruiting
General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, 94535, United States; Recruiting
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, 90801-1428, United States; Recruiting
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States; Recruiting
Kaiser Permanente Medical Center - Sacramento, Sacramento, California, 95825, United States; Recruiting
Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, 95051-5386, United States; Recruiting
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California, 92120, United States; Recruiting
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, 92354, United States; Recruiting
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, 94304, United States; Recruiting
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States; Recruiting
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States; Recruiting
Santa Barbara Cottage Hospital, Santa Barbara, California, 93102, United States; Recruiting
Southern California Permanente Medical Group, Downey, California, 90242, United States; Recruiting
Sutter Cancer Center, Sacramento, California, 95816, United States; Recruiting
UCSF Comprehensive Cancer Center, San Francisco, California, 94143, United States; Recruiting
Colorado
Children's Hospital Cancer Center, Denver, Colorado, 80218, United States; Recruiting
Presbyterian - St. Luke's Medical Center, Denver, Colorado, 80218, United States; Recruiting
Connecticut
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, 06360-7106, United States; Recruiting
Yale Comprehensive Cancer Center, New Haven, Connecticut, 06520-8064, United States; Recruiting
Delaware
Alfred I. duPont Hospital for Children, Wilmington, Delaware, 19899, United States; Recruiting
District of Columbia
Children's National Medical Center, Washington, District of Columbia, 20010-2970, United States; Recruiting
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States; Recruiting
Florida
All Children's Hospital, St. Petersburg, Florida, 33701, United States; Recruiting
Baptist-South Miami Regional Cancer Program, Miami, Florida, 33176-2197, United States; Recruiting
Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States; Recruiting
Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States; Recruiting
Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States; Recruiting
Jackson Memorial Hospital, Miami, Florida, 33136, United States; Recruiting
Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida, 33021, United States; Recruiting
Miami Children's Hospital, Miami, Florida, 33155, United States; Recruiting
Nemours Children's Clinic, Jacksonville, Florida, 32207, United States; Recruiting
Nemours Children's Clinic-Orlando, Orlando, Florida, 32806, United States; Recruiting
Sacred Heart Children's Hospital, Pensacola, Florida, 32504, United States; Recruiting
St. Joseph's Children's Hospital, Tampa, Florida, 33677-4227, United States; Recruiting
St. Mary's Hospital, West Palm Beach, Florida, 33407, United States; Recruiting
University of Florida Shands Cancer Center, Gainesville, Florida, 32610-0296, United States; Recruiting
Georgia
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, 30342, United States; Recruiting
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, 31405, United States; Recruiting
MBCCOP-Medical College of Georgia Cancer Center, Augusta, Georgia, 30912-4000, United States; Recruiting
Medical Center of Central Georgia, Macon, Georgia, 31201, United States; Recruiting
Hawaii
Cancer Research Center of Hawaii, Honolulu, Hawaii, 96813, United States; Recruiting
MBCCOP - Hawaii, Honolulu, Hawaii, 96813, United States; Recruiting
Tripler Army Medical Center, Honolulu, Hawaii, 96859-5000, United States; Recruiting
Idaho
Mountain States Tumor Institute - Boise, Boise, Idaho, 83712, United States; Recruiting
Illinois
Advocate Hope Children's Hospital, Oak Lawn, Illinois, 60453, United States; Recruiting
Children's Memorial Hospital - Chicago, Chicago, Illinois, 60614, United States; Recruiting
Lutheran General Cancer Care Center, Park Ridge, Illinois, 60068-1174, United States; Recruiting
Rush University Medical Center, Chicago, Illinois, 60612, United States; Recruiting
Saint Jude Midwest Affiliate, Peoria, Illinois, 61637, United States; Recruiting
Southern Illinois University School of Medicine, Springfield, Illinois, 62794-9658, United States; Recruiting
University of Chicago Cancer Research Center, Chicago, Illinois, 60601, United States; Recruiting
University of Illinois Medical Center, Chicago, Illinois, 60612, United States; Recruiting
Indiana
Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, 46202-5225, United States; Recruiting
St. Vincent Hospitals and Health Care Centers, Indianapolis, Indiana, 46260, United States; Recruiting
Iowa
Blank Children's Hospital, Des Moines, Iowa, 50308, United States; Recruiting
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States; Recruiting
John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, 50309, United States; Recruiting
Kansas
Wesley Medical Center, Wichita, Kansas, 67214, United States; Recruiting
Kentucky
Kosair Children's Hospital, Louisville, Kentucky, 40202-3830, United States; Recruiting
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, 40536-0284, United States; Recruiting
Louisiana
Children's Hospital of New Orleans, New Orleans, Louisiana, 70118, United States; Recruiting
MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, 70112, United States; Recruiting
Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States; Recruiting
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, 70112, United States; Recruiting
Maine
CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, 04401, United States; Recruiting
Maine Children's Cancer Program, Scarborough, Maine, 04074-9308, United States; Recruiting
Maryland
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, 21215, United States; Recruiting
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201-1595, United States; Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-2410, United States; Recruiting
Walter Reed Army Medical Center, Silver Spring, Maryland, 20910, United States; Recruiting
Massachusetts
Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts, 01107, United States; Recruiting
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Recruiting
Floating Hospital for Children, Boston, Massachusetts, 02111, United States; Recruiting
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, 01655, United States; Recruiting
Michigan
Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, 48910, United States; Recruiting
Bronson Methodist Hospital, Kalamazoo, Michigan, 49007-5364, United States; Recruiting
CCOP - Beaumont, Royal Oak, Michigan, 48073-6769, United States; Recruiting
Children's Hospital of Michigan, Detroit, Michigan, 48201, United States; Recruiting
DeVos Children's Hospital, Grand Rapids, Michigan, 49503, United States; Recruiting
Hurley Medical Center, Flint, Michigan, 48503, United States; Recruiting
Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, 48202, United States; Recruiting
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0914, United States; Recruiting
Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan, 48236, United States; Recruiting
William Beaumont Hospital - Royal Oak, Royal Oak, Michigan, 48073-6769, United States; Recruiting
Minnesota
Children's Hospitals and Clinics - Minneapolis/St. Paul, Minneapolis, Minnesota, 55404, United States; Recruiting
Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States; Recruiting
St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota, 55805, United States; Recruiting
Mississippi
University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, United States; Recruiting
Missouri
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, 63104, United States; Recruiting
Children's Mercy Hospital, Kansas City, Missouri, 64108, United States; Recruiting
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, 65203, United States; Recruiting
St. Louis Children's Hospital, Saint Louis, Missouri, 63110, United States; Recruiting
Nebraska
Children's Hospital of Omaha, Omaha, Nebraska, 68114, United States; Recruiting
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-2168, United States; Recruiting
Nevada
Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States; Recruiting
New Hampshire
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States; Recruiting
New Jersey
Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States; Recruiting
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08903, United States; Recruiting
Newark Beth Israel Medical Center, Newark, New Jersey, 07112-2094, United States; Recruiting
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, 07503, United States; Recruiting
Valerie Fund Children's Center at Atlantic Health, Summit, New Jersey, 07901, United States; Recruiting
New Mexico
University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, 87131, United States; Recruiting
New York
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, 10461, United States; Recruiting
Brookdale University Hospital and Medical Center, Brooklyn, New York, 11212, United States; Recruiting
Brooklyn Hospital Center, Brooklyn, New York, 11201-5493, United States; Recruiting
Cancer Center of Albany Medical Center, Albany, New York, 12208, United States; Recruiting
Comprehensive Cancer Center at Maimonides Medical Center, Brooklyn, New York, 11219, United States; Recruiting
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, 10032, United States; Recruiting
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, 14642, United States; Recruiting
Long Island Cancer Center at Stony Brook University Hospital, Stony Brook, New York, 11794, United States; Recruiting
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States; Recruiting
Mount Sinai School of Medicine, New York, New York, 10029, United States; Recruiting
New York Medical College, Valhalla, New York, 10595, United States; Recruiting
New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States; Recruiting
Schneider Children's Hospital, New Hyde Park, New York, 11042, United States; Recruiting
SUNY Downstate Medical Center, Brooklyn, New York, 11203, United States; Recruiting
SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, 28232-2861, United States; Recruiting
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1081, United States; Recruiting
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States; Recruiting
Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital, Greenville, North Carolina, 27858-4354, United States; Recruiting
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599, United States; Recruiting
Mission Hospitals, Asheville, North Carolina, 28801, United States; Recruiting
Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, 28233, United States; Recruiting
North Dakota
Dakota Cancer Institute at Innovis Health - Dakota Clinic, Fargo, North Dakota, 58103-4940, United States; Recruiting
Ohio
Children's Hospital Medical Center of Akron, Akron, Ohio, 44308-1062, United States; Recruiting
Children's Medical Center - Dayton, Dayton, Ohio, 45404, United States; Recruiting
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States; Recruiting
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States; Recruiting
Columbus Children's Hospital, Columbus, Ohio, 43205-2696, United States; Recruiting
Forum Health-Tod Childrens Hospital, Youngstown, Ohio, 44501, United States; Recruiting
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, 44106-5065, United States; Recruiting
St. Vincent Mercy Medical Center, Toledo, Ohio, 43608, United States; Recruiting
Toledo Children's Hospital, Toledo, Ohio, 43601, United States; Recruiting
Oklahoma
CCOP - Oklahoma, Tulsa, Oklahoma, 74136, United States; Recruiting
Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States; Recruiting
Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, 74136, United States; Recruiting
Oregon
CCOP - Columbia River Oncology Program, Portland, Oregon, 97225, United States; Recruiting
Doernbecher Children's Hospital at Oregon Health & Science University, Portland, Oregon, 97239-3098, United States; Recruiting
Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, 97227, United States; Recruiting
Pennsylvania
Children's Hospital at Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States; Recruiting
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States; Recruiting
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States; Recruiting
Geisinger Medical Center, Danville, Pennsylvania, 17822-1320, United States; Recruiting
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, 19134-1095, United States; Recruiting
Rhode Island
Rhode Island Hospital, Providence, Rhode Island, 02903, United States; Recruiting
South Carolina
Children's Hospital of Greenville Hospital System, Greenville, South Carolina, 29605, United States; Recruiting
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, 29425-0721, United States; Recruiting
Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, 29203, United States; Recruiting
South Dakota
Avera Cancer Institute, Sioux Falls, South Dakota, 57105-1080, United States; Recruiting
Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, 57117-5039, United States; Recruiting
Tennessee
East Tennessee Children's Hospital, Knoxville, Tennessee, 37901, United States; Recruiting
East Tennessee State University Cancer Center at Johnson City Medical Center, Johnson City, Tennessee, 37614-0622, United States; Recruiting
St. Jude Children's Research Hospital, Memphis, Tennessee, 38105-2794, United States; Recruiting
Vanderbilt Children's Hospital, Nashville, Tennessee, 37232-6310, United States; Recruiting
Texas
Baylor College of Medicine, Houston, Texas, 77030, United States; Recruiting
CCOP - Scott and White Hospital, Temple, Texas, 76508, United States; Recruiting
Center for Cancer Prevention and Care at Scott and White Clinic, Temple, Texas, 76508, United States; Recruiting
Children's Hospital of Austin, Austin, Texas, 78701, United States; Recruiting
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, 76104, United States; Recruiting
Covenant Children's Hospital, Lubbock, Texas, 79410, United States; Recruiting
MBCCOP - South Texas Pediatrics, San Antonio, Texas, 78229-3900, United States; Recruiting
MD Anderson Cancer Center at University of Texas, Houston, Texas, 77030-4009, United States; Recruiting
Medical City Dallas Hospital, Dallas, Texas, 75230, United States; Recruiting
Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas, 78229-3902, United States; Recruiting
San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, 78236, United States; Recruiting
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, 75390-9063, United States; Recruiting
Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, 79106, United States; Recruiting
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78207, United States; Recruiting
University of Texas Medical Branch, Galveston, Texas, 77555-0209, United States; Recruiting
Utah
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, 84112, United States; Recruiting
Vermont
Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States; Recruiting
Virginia
Cancer Center at the University of Virginia, Charlottesville, Virginia, 22908, United States; Recruiting
Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia, 24029, United States; Recruiting
Children's Hospital of the King's Daughters, Norfolk, Virginia, 23507, United States; Recruiting
INOVA Fairfax Hospital, Falls Church, Virginia, 22042-3300, United States; Recruiting
Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, 23298-0121, United States; Recruiting
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: June 2004
Last Updated: March 28, 2005
Record first received: January 9, 2004
ClinicalTrials.gov Identifier: NCT00075725
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- TG (Drug Digest)
- Thioguanine (Drug Digest)

Not Signed In -

